share_log

HC Wainwright & Co. Maintains Buy on Taro Pharmaceutical Indus, Lowers Price Target to $54

Benzinga Real-time News ·  Aug 15, 2022 18:44

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Taro Pharmaceutical Indus (NYSE:TARO) with a Buy and lowers the price target from $73 to $54.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment